TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34315413
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (25 µg)
Study: 35871120
Drug: HNLP (High
Approvals — FDA: no, EMA: no, PMDA: no
Description: HNLP (High Nitrate Low Phenolic) - 50g of lettuce containing 530mg nitrate and 11mg phenolic compounds
Study: 35871120
Drug: LNHP (Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNHP (Low Nitrate High Phenolic) - 50g of lettuce containing 3mg nitrate and 77mg phenolic compounds
Study: 33394979
Drug: Single Trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Trigger Point Injection (TPI)
Study: 33499848
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (15 mg/kg in 100 mL of saline solution) administered 10 min before tourniquet release
Study: 33499848
Drug: Intra-articular TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular TXA (15 mg/kg in 100 mL of saline solution) injected via drainage tube
Study: 33499848
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent volume of normal saline administered into the knee joint cavity and intravenously)
Study: 32646498
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (control)
Study: 35986947
Drug: Methionine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine plus Disaccharide injection (25 g/L maltose + 25 g/L sucrose + 5 g/L Met + 7.5 g/L NaCl)
Study: 35986947
Drug: Non-injection (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-injection (control group)
Study: 34233152
Drug: Finite Difference
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finite Difference Method (FDM) for modeling tablet disintegration
Study: 34389930
Drug: Insulin pumps
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin pumps
Study: 38750866
Drug: Vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 10 mg
Study: 35798020
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g prunes
Study: 32604121
Drug: Lu-DOTATATE (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu-DOTATATE (median cumulative dose of 27 GBq, range 13.3-41.3 GBq, over 2-7 cycles) and 1250 mg/m capecitabine from days 0 to 14 of each PRRT cycle
Study: 35719637
Drug: Two-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-agent chemotherapy regimen (T+I)
Study: 37192642
Drug: MDMA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (100 mg)
Study: 33558678
Drug: Topiramate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (200 mg/day)
Study: 34959951
Drug: Potassium gluconate
Normalized name: Potassium Gluconate
DrugBank: Potassium gluconate (DB13620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium gluconate supplementation (1000 mg/day added to a basal diet of 2300 mg/day)
Study: 34959951
Drug: Control (basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (basal diet of 2300 mg/day potassium)
Study: 35030036
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg once daily and rituximab 375 mg/m2 (total of eight doses)
Study: 35656793
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with dupilumab
Study: 35388606
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin (0.5 mg/kg once daily for 16 weeks) + SM peeling (20% salicylic and 10% mandelic acid every four weeks for 16 weeks)
Study: 32623812
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (monthly for 2 years)
Study: 33313936
Drug: Daylight photodynamic
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight photodynamic therapy (5 full-face sessions over 2 years)
Study: 33313936
Drug: Daylight photodynamic
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight photodynamic therapy
Study: 36424554
Drug: Left nostril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left nostril (Group L, n=25)
Study: 36424554
Drug: Left nostril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left nostril (Group L)
Study: 33370024
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only
Study: 33451057
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) per day (0.3 g EPA and 1.3 g DHA) in a microencapsulated powder
Study: 32694001
Drug: Home-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based physical exercise (60 minutes twice a week for 24 months)
Study: 34849918
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing regimens of etrolizumab
Study: 36468650
Drug: CBTp (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBTp (Cognitive Behavioral Therapy for parasomnias)
Study: 32449002
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPI)
Study: 37482940
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (OMT)
Study: 32503556
Drug: Misoprostol (800mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (800mcg sublingual for treatment, 600mcg oral for prophylaxis)
Study: 34878933
Drug: Laser Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser Therapy (LT) (808 nm, 100 mW, 40 sec/point, 4 J/point, intra/extraoral)
Study: 33216013
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) group program PROTECT+, 4 sessions
Study: 32627474
Drug: Zhibitai Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhibitai Capsules combined with statins
Study: 38421679
Drug: Glucocorticoid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid injection
Study: 39305035
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy
Study: 35040506
Drug: Sirolimus (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (2-6 mg daily) for 48 weeks
Study: 35882375
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate (OC group) - 300 mL/bottle
Study: 35882375
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (OP group) - 300 mL distilled water
Study: 34854808
Drug: Primary trabeculectomy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary trabeculectomy treatment - trabeculectomy augmented with mitomycin C
Study: 34854808
Drug: Primary medical
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary medical treatment - escalating medical management with glaucoma eye drops
Study: 33049730
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen at 10 l/min until delivery
Study: 34687435
Drug: Copaiba oil
Normalized name: COPAIBA OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copaiba oil in silicone gel, applied twice a day for 84 days
Study: 36160864
Drug: Acetazolamide (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (375 mg/d)
Study: 33576219
Drug: Curcumin gel
DrugBank: Curcumin sulfate (DB14635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin gel (Curenext)
Study: 33576219
Drug: Aloe Vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe Vera gel (Aloe Vera 100% relief)
Study: 37103493
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment as usual)
Study: 35717193
Drug: Community-wide mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide mass drug administration (MDA) with efficient duration of delivery (within ten days)
Study: 35961520
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg intravenously) every 4 weeks for up to 24 months
Study: 36042582
Drug: Low-frequency electric
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency electric pulse therapy (LFEPT) combined with tropisetron hydrochloride and dexamethasone hydrochloride
Study: 36042582
Drug: Low-frequency electric
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency electric pulse therapy (LFEPT)
Study: 35179082
Drug: Cognitive-Behavioural Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioural Therapy
Study: 36410223
Drug: Bupropion 75
Normalized name: buPROPion 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 75 mg twice daily for twelve weeks
Study: 34188459
Drug: ICT-based multicomponent
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICT-based multicomponent program applied twice per week, once per day for 12 weeks, 30 min per session
Study: 36442484
Drug: Rezafungin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezafungin (400 mg in week 1, followed by 200 mg weekly, for a total of two to four doses)
Study: 36442484
Drug: Caspofungin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (70 mg loading dose on day 1, followed by 50 mg daily)
Study: 33838756
Drug: ChAdOx1 nCoV‐19
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV‐19 vaccine (low dose)
Study: 33838756
Drug: ChAdOx1 nCoV‐19
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV‐19 vaccine (high dose)
Study: 35584529
Drug: Mannitol solution
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol solution
Study: 35807836
Drug: C. rabens
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. rabens extract capsule
Study: 32352676
Drug: Contractubex gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contractubex gel applied 3 times a day for 9 months
Study: 32352676
Drug: No regular
Normalized name: Aveeno Regular Bath
Approvals — FDA: no, EMA: no, PMDA: no
Description: No regular therapy (control group)
Study: 32883514
Drug: High antimüllerian
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antimüllerian hormone (AMH) levels in women with PCOS
Study: 38497150
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment
Study: 32272513
Drug: Ceramide-containing moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramide-containing moisturizing cream
Study: 32835925
Drug: donepezil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil (10 mg/day)
Study: 36198467
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with usual daily activities
Study: 33904792
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control (LA without laser output plus conventional treatment)
Study: 35971655
Drug: galcanezumab-120 mg
Normalized name: galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: galcanezumab-120 mg
Study: 35971655
Drug: galcanezumab-240 mg
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: galcanezumab-240 mg
Study: 35971655
Drug: previous-galcanezumab-120 mg
Normalized name: galcanezumab-gnlm 120 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: previous-galcanezumab-120 mg
Study: 35971655
Drug: previous-galcanezumab-240 mg
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: previous-galcanezumab-240 mg
Study: 34851211
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (30 sessions of conventional treatment, 5 sessions per week)
Study: 32909675
Drug: Anifrolumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anifrolumab (300 mg)
Study: 35477563
Drug: Control lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control lozenges
Study: 35417301
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of E. coli-produced HPV-16/18 bivalent vaccine
Study: 32712034
Drug: Trigger Point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger Point Injections (TPIs) with 1% lidocaine
Study: 32437568
Drug: Pedometer-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer-based intervention with weekly step goals
Study: 33158079
Drug: 85 g
Normalized name: UREA 17 g in 85 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 85 g of mango intake
Study: 33380704
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg/day)
Study: 32456272
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + low-volume HIIT
Study: 32456272
Drug: No Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Metformin + MICT
Study: 32456272
Drug: No Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Metformin + high-volume HIIT
Study: 32456272
Drug: No Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Metformin + low-volume HIIT
Study: 37418263
Drug: Erythropoietin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin treatment
Study: 36376888
Drug: Venetoclax combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax combined with low dose cytarabine (VEN + LDAC)
Study: 36376888
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care intensive chemotherapy (IC)
Study: 36152639
Drug: Tirzepatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (5 mg, 10 mg, or 15 mg)
Study: 32740593
Drug: Closed-incision negative-pressure
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-incision negative-pressure therapy
Study: 34162822
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera mouthwash (20 ccs three times daily for 14 days)
Study: 34162822
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (control group, 20 ccs three times daily for 14 days)
Study: 32567941
Drug: Triticum vulgare
Normalized name: Triticum vulgare extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triticum vulgare (TV) spray, gluten-free, used twice daily after toothbrushing for 2 weeks
Study: 33768368
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate Dry Powder Inhaler B-3.8 (500 μg)
Study: 33462512
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (20 g per day)
Study: 35413431
Drug: Interventional multimodal
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventional multimodal sleep pathway including nursing‐directed nonpharmacologic measures, low‐dose zolpidem and melatonin at bedtime.
Study: 34509197
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (17P) 250 mg intramuscularly once per week starting between 16 and 24 weeks of gestation until delivery, stillbirth, or reaching term (37 weeks)
Study: 34509197
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered in the same manner as 17P
Study: 32084053
Drug: Positively Smoke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positively Smoke Free group therapy
Study: 34921572
Drug: G-CEM ONE
Normalized name: CEM-Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CEM ONE Adhesive Enhancing Primer (GCO-AEP) + GCO
Study: 34540645
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% 20 mL (Control)
Study: 34540645
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% 20 mL plus 4mg dexamethasone
Study: 34540645
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% 20 mL plus 75 mcg dexmedetomidine
Study: 32993775
Drug: ACAT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACAT group (Cognitive-behavioral family therapy)
Study: 34413169
Drug: TLR agonists
Normalized name: TLR-AD1
DrugBank: TLR-AD1 (DB18241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLR agonists only
Study: 32711800
Drug: Emtricitabine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine (200 mg) and tenofovir alafenamide (25 mg) daily
Study: 32711800
Drug: Emtricitabine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) daily
Study: 38864155
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of β-lactam antibiotics (piperacillin-tazobactam or meropenem)
Study: 36424257
Drug: 4vHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4vHPV vaccine
Study: 34435513
Drug: 5 mg·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg·kg‐1 placebo (PLA)
Study: 34435513
Drug: 5 mg·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg·kg‐1 caffeine (CAF)
Study: 35238725
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) belimumab 10 mg/kg dose Q2W for three doses, then 10 mg/kg Q4W thereafter
Study: 35238725
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) belimumab 400 mg dose QW for four doses, then 200 mg QW thereafter
Study: 33291727
Drug: Static-sequential-permanent pictures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static-sequential-permanent pictures condition (n = 36)
Study: 33291727
Drug: Static-sequential-transient pictures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static-sequential-transient pictures condition (n = 29)
Study: 34280843
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta treatment
Study: 38549128
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (BMT)
Study: 33823051
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication
Study: 32143730
Drug: Capecitabine metronomic
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine metronomic chemotherapy
Study: 32143730
Drug: Capecitabine conventional
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine conventional chemotherapy
Study: 36354040
Drug: LY3437943 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3437943 3 mg
Study: 36354040
Drug: LY3437943 3/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3437943 3/6 mg
Study: 36354040
Drug: LY3437943 3/6/9/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3437943 3/6/9/12 mg
Study: 34403548
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg oral midazolam
Study: 34414678
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg once daily for 8 weeks
Study: 35143622
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with bortezomib and DA‐EPOCH‐R for 6 cycles followed by observation in responding patients
Study: 35143622
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with bortezomib and DA‐EPOCH‐R for 6 cycles followed by bortezomib maintenance in responding patients
Study: 33788452
Drug: Governor Vessel
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Governor Vessel moxibustion therapy, applied once a week for 8 weeks.
Study: 33788452
Drug: Atorvastatin calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin calcium tablets (10 mg) once daily for 8 weeks (Control).
Study: 33788452
Drug: Governor Vessel
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Governor Vessel moxibustion therapy (I) vs Atorvastatin (C) for CAS clinical effect.
Study: 35483396
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy alone
Study: 36480346
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction program combined with music therapy
Study: 32931612
Drug: 400 units
Normalized name: alpha-D-galactosidase 400 units oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 units of vitamin E and 1,000 mg of vitamin C/day
Study: 32640132
Drug: Nemolizumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab (60 mg subcutaneously every 4 weeks)
Study: 32800029
Drug: Daily inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily inhalation of budesonide 200 μg/day
Study: 32800029
Drug: Intermittent inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent inhalation of budesonide 200 μg/day
Study: 35133884
Drug: Blonanserin 16
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin 16 mg/day
Study: 35133884
Drug: Blonanserin 8
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin 8 mg/day